---
title: Drug of choice for specific infections and conditions
videoId: SIdKlpcoqMo
---

From: [[marrowmed]] <br/> 

This article outlines specific drug choices for various infections and medical conditions, drawing information from recent pharmacology discussions.

## Antimicrobials and Antiparasitics

### Fasciola Hepatica
*   **Albendazole** is effective against nematodes and cestodes, but not against trematodes like *Fasciola hepatica* <a class="yt-timestamp" data-t="00:02:00">[00:02:00]</a>.
*   The drug of choice for *Fasciola hepatica* is **Triclabendazole** <a class="yt-timestamp" data-t="00:02:08">[00:02:08]</a>.
*   For all other trematodes, **Praziquantel** is used <a class="yt-timestamp" data-t="00:02:13">[00:02:13]</a>.

### Malaria
All of the following drugs can be used in uncomplicated [[treatment_strategies_for_malaria | malaria]] <a class="yt-timestamp" data-t="00:04:18">[00:04:18]</a>:
*   **Chloroquine** <a class="yt-timestamp" data-t="00:04:22">[00:04:22]</a>
*   **Artemether** (with lumefantrine) <a class="yt-timestamp" data-t="00:04:25">[00:04:25]</a>
*   **Sulfadoxine-Pyrimethamine** <a class="yt-timestamp" data-t="00:04:28">[00:04:28]</a>
*   **Primaquine** is used for the prevention of malaria relapse, not for symptomatic treatment of uncomplicated malaria <a class="yt-timestamp" data-t="00:04:32">[00:04:32]</a>, <a class="yt-timestamp" data-t="00:05:05">[00:05:05]</a>.

### HIV Infection
*   **Ibalizumab** is the only drug that binds to CD4 receptors and has action on both CCR5 and CXCR4 tropic HIV infection <a class="yt-timestamp" data-t="00:05:34">[00:05:34]</a>, <a class="yt-timestamp" data-t="00:05:57">[00:05:57]</a>. It is administered via intravenous (IV) route <a class="yt-timestamp" data-t="00:06:02">[00:06:02]</a>.
*   **Maraviroc** and **Vicriviroc** are CCR5 inhibitors <a class="yt-timestamp" data-t="00:05:41">[00:05:41]</a>.
*   **Elvitegravir** is an integrase inhibitor <a class="yt-timestamp" data-t="00:05:45">[00:05:45]</a>.
*   **Ritonavir** and **Nelfinavir** are protease inhibitors <a class="yt-timestamp" data-t="00:05:50">[00:05:50]</a>.

### Tuberculosis (TB)
*   **Pretomanid** is a new drug for TB, belonging to the nitroimidazole class <a class="yt-timestamp" data-t="00:12:15">[00:12:15]</a>, <a class="yt-timestamp" data-t="00:12:57">[00:12:57]</a>.
    *   It is given for pre-extensively drug-resistant (pre-XDR) TB <a class="yt-timestamp" data-t="00:12:26">[00:12:26]</a>, <a class="yt-timestamp" data-t="00:12:29">[00:12:29]</a>. Pre-XDR TB is defined as multi-drug resistant (MDR) TB plus fluoroquinolone resistance <a class="yt-timestamp" data-t="00:12:34">[00:12:34]</a>, <a class="yt-timestamp" data-t="00:12:37">[00:12:37]</a>.
    *   It is contraindicated in patients on enzyme-inducing drugs because it is metabolized by microsomal enzymes <a class="yt-timestamp" data-t="00:12:41">[00:12:41]</a>, <a class="yt-timestamp" data-t="00:12:44">[00:12:44]</a>.
    *   Its mechanism involves producing free nitro anion radicals (reactive nitrogen species), not reactive oxygen species <a class="yt-timestamp" data-t="00:13:05">[00:13:05]</a>, <a class="yt-timestamp" data-t="00:13:12">[00:13:12]</a>.
*   New regimens in India:
    *   **BPaL** (Bedaquiline, Pretomanid, Linezolid) is for pre-XDR TB <a class="yt-timestamp" data-t="00:13:28">[00:13:28]</a>, <a class="yt-timestamp" data-t="00:13:31">[00:13:31]</a>, <a class="yt-timestamp" data-t="00:13:55">[00:13:55]</a>.
    *   **BPaLM** (Bedaquiline, Pretomanid, Linezolid, Moxifloxacin) was approved in September for MDR-TB <a class="yt-timestamp" data-t="00:13:37">[00:13:37]</a>, <a class="yt-timestamp" data-t="00:13:40">[00:13:40]</a>, <a class="yt-timestamp" data-t="00:13:46">[00:13:46]</a>, <a class="yt-timestamp" data-t="00:13:59">[00:13:59]</a>.

## Cardiovascular Conditions

### Hyperlipidemia in Atherosclerotic Cardiovascular Disease (ASBD)
The primary aim in ASBD is to decrease LDL levels, not triglycerides <a class="yt-timestamp" data-t="00:03:08">[00:03:08]</a>, <a class="yt-timestamp" data-t="00:03:10">[00:03:10]</a>.
Drugs used to decrease LDL:
*   **Ezetimibe** <a class="yt-timestamp" data-t="00:03:21">[00:03:21]</a>
*   **Evolocumab** <a class="yt-timestamp" data-t="00:03:24">[00:03:24]</a>
*   **Bempedoic acid** <a class="yt-timestamp" data-t="00:03:34">[00:03:34]</a>
*   **Gemfibrozil** (a fibrate) is used to decrease triglycerides, not LDL <a class="yt-timestamp" data-t="00:03:27">[00:03:27]</a>, <a class="yt-timestamp" data-t="00:03:30">[00:03:30]</a>.

## Oncology

### BRCA-Positive Breast Cancer
*   **Olaparib**, **Rucaparib**, and **Talazoparib** are PARP (Poly ADP-ribose polymerase) inhibitors, indicated for BRCA-positive breast cancer <a class="yt-timestamp" data-t="00:07:26">[00:07:26]</a>, <a class="yt-timestamp" data-t="00:07:36">[00:07:36]</a>, <a class="yt-timestamp" data-t="00:07:40">[00:07:40]</a>, <a class="yt-timestamp" data-t="00:07:47">[00:07:47]</a>.
*   **Palbociclib** is a CDK (cyclin-dependent kinase) 4 and 6 inhibitor, also used in breast cancer <a class="yt-timestamp" data-t="00:07:54">[00:07:54]</a>, <a class="yt-timestamp" data-t="00:07:57">[00:07:57]</a>, <a class="yt-timestamp" data-t="00:08:00">[00:08:00]</a>.
*   **Regorafenib** is a BRAF inhibitor used in malignant melanoma <a class="yt-timestamp" data-t="00:08:05">[00:08:05]</a>, <a class="yt-timestamp" data-t="00:08:08">[00:08:08]</a>.
*   **Vandetanib** is a VEGF (Vascular Endothelial Growth Factor) or tyrosine kinase inhibitor <a class="yt-timestamp" data-t="00:08:12">[00:08:12]</a>, <a class="yt-timestamp" data-t="00:08:16">[00:08:16]</a>.

## Autoimmune/Inflammatory Conditions

### Ulcerative Colitis
For moderate to severe ulcerative colitis not responding to anti-TNF-alpha agents, **Tofacitinib** (a JAK inhibitor) is a preferred option <a class="yt-timestamp" data-t="00:08:28">[00:08:28]</a>, <a class="yt-timestamp" data-t="00:08:31">[00:08:31]</a>, <a class="yt-timestamp" data-t="00:08:33">[00:08:33]</a>, <a class="yt-timestamp" data-t="00:08:44">[00:08:44]</a>.
*   JAK inhibitors are oral drugs <a class="yt-timestamp" data-t="00:09:09">[00:09:09]</a>, <a class="yt-timestamp" data-t="00:09:11">[00:09:11]</a>.
*   Examples include **Baricitinib**, **Upadacitinib**, and **Tofacitinib** <a class="yt-timestamp" data-t="00:09:15">[00:09:15]</a>, <a class="yt-timestamp" data-t="00:09:27">[00:09:27]</a>.

## Neurology

### Partial Seizures
*   **Lacosamide** acts on sodium channels by potentiating slow sodium channel inactivation, which blocks repetitive firing of neurons responsible for partial seizures <a class="yt-timestamp" data-t="00:06:11">[00:06:11]</a>, <a class="yt-timestamp" data-t="00:06:26">[00:06:26]</a>, <a class="yt-timestamp" data-t="00:06:30">[00:06:30]</a>, <a class="yt-timestamp" data-t="00:06:56">[00:06:56]</a>, <a class="yt-timestamp" data-t="00:06:58">[00:06:58]</a>.
*   **Tiagabine** is a GABA (gamma-aminobutyric acid) transporter inhibitor, used for the treatment of partial seizures <a class="yt-timestamp" data-t="00:16:00">[00:16:00]</a>, <a class="yt-timestamp" data-t="00:16:06">[00:16:06]</a>, <a class="yt-timestamp" data-t="00:16:15">[00:16:15]</a>, <a class="yt-timestamp" data-t="00:16:17">[00:16:17]</a>.

## Toxicology and Antidotes

### Antidotes for Toxicity
*   **Organophosphorus poisoning**: Antidote is **Atropine** <a class="yt-timestamp" data-t="00:10:08">[00:10:08]</a>, <a class="yt-timestamp" data-t="00:10:11">[00:10:11]</a>, <a class="yt-timestamp" data-t="00:10:13">[00:10:13]</a>.
*   **Atropine toxicity**: Antidote is **Physostigmine** <a class="yt-timestamp" data-t="00:10:16">[00:10:16]</a>, <a class="yt-timestamp" data-t="00:10:18">[00:10:18]</a>.
*   **Valproate-induced hepatotoxicity**: Antidote is **L-carnitine** <a class="yt-timestamp" data-t="00:10:21">[00:10:21]</a>.
*   **Benzodiazepine overdose**: Antidote is **Flumazenil** <a class="yt-timestamp" data-t="00:10:26">[00:10:26]</a>, <a class="yt-timestamp" data-t="00:10:27">[00:10:27]</a>.
*   **Arsenic toxicity**: Antidote is **Dimercaprol** (not deferoxamine) <a class="yt-timestamp" data-t="00:10:29">[00:10:29]</a>. **Desferoxamine** is an iron chelating agent <a class="yt-timestamp" data-t="00:10:31">[00:10:31]</a>, <a class="yt-timestamp" data-t="00:10:33">[00:10:33]</a>.

## Drug-Specific Information

### Phenytoin
*   Acute oral overdose of **Phenytoin** primarily results in cerebellar and vestibular symptoms such as ataxia, diplopia, and dysarthria <a class="yt-timestamp" data-t="00:14:14">[00:14:14]</a>, <a class="yt-timestamp" data-t="00:14:16">[00:14:16]</a>, <a class="yt-timestamp" data-t="00:14:21">[00:14:21]</a>, <a class="yt-timestamp" data-t="00:14:24">[00:14:24]</a>.
*   High doses are associated with marked cerebellar atrophy <a class="yt-timestamp" data-t="00:14:28">[00:14:28]</a>.
*   IV administration rate should be less than 50 mg/minute to minimize complications like cardiac arrhythmias and CNS depression <a class="yt-timestamp" data-t="00:14:43">[00:14:43]</a>, <a class="yt-timestamp" data-t="00:14:46">[00:14:46]</a>, <a class="yt-timestamp" data-t="00:14:51">[00:14:51]</a>, <a class="yt-timestamp" data-t="00:15:01">[00:15:01]</a>, <a class="yt-timestamp" data-t="00:15:03">[00:15:03]</a>.
*   Phenytoin is not given to all patients with seizures regardless of cardiac arrhythmia, hypotension, or CNS depression <a class="yt-timestamp" data-t="00:15:10">[00:15:10]</a>.
*   Therapeutic drug monitoring (TDM) and dose adjustment are performed based on plasma concentration when cerebellar and vestibular symptoms occur with high doses or acute oral overdose <a class="yt-timestamp" data-t="00:15:35">[00:15:35]</a>, <a class="yt-timestamp" data-t="00:15:37">[00:15:37]</a>, <a class="yt-timestamp" data-t="00:15:39">[00:15:39]</a>, <a class="yt-timestamp" data-t="00:15:42">[00:15:42]</a>.

## Pharmacokinetics

### Half-Life Calculation
The formula for half-life (T1/2) is:
T1/2 = (0.693 * Volume of Distribution) / Clearance <a class="yt-timestamp" data-t="00:00:53">[00:00:53]</a>, <a class="yt-timestamp" data-t="00:00:56">[00:00:56]</a>
For quick calculation, 0.693 can be rounded off to 0.7 <a class="yt-timestamp" data-t="00:01:02">[00:01:02]</a>, <a class="yt-timestamp" data-t="00:01:05">[00:01:05]</a>.

**Example Calculation (Digoxin):**
*   Weight: 46 kg <a class="yt-timestamp" data-t="00:00:27">[00:00:27]</a>
*   Volume of Distribution (VD): 6 L/kg <a class="yt-timestamp" data-t="00:00:31">[00:00:31]</a>
*   Clearance: 4.6 L/hour <a class="yt-timestamp" data-t="00:00:34">[00:00:34]</a>

1.  Total VD = 46 kg * 6 L/kg = 276 L <a class="yt-timestamp" data-t="00:01:12">[00:01:12]</a>, <a class="yt-timestamp" data-t="00:01:17">[00:01:17]</a>.
2.  T1/2 = (0.7 * 276 L) / 4.6 L/hour = 42 hours <a class="yt-timestamp" data-t="00:01:25">[00:01:25]</a>, <a class="yt-timestamp" data-t="00:01:31">[00:01:31]</a>.